



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service  
Food and Drug Administration

g 1547d

San Francisco District  
1431 Harbor Bay Parkway  
Alameda, CA 94502-7070  
Telephone: 510/337-6700

**WARNING LETTER**

July 19, 2001

via Federal Express

MQSA Facility ID: 119990

Inspection ID: 1199900009

FDA Reference #: 2951743

Gil Silbernagel  
Sutter Lakeside Hospital  
5176 Hill Road East  
P.O. Box 729  
Lakeport, CA 95453

Dear Gil Silbernagel:

We are writing to you because on June 19, 2001, your facility was inspected by a representative of the State of California, acting in behalf of the Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 1 findings at your facility:

Level 1: Processor QC records were missing 8 out of 23 days of operation in month 04/2001. Processor QC records missing 35%, for processor 0000000001, [REDACTED] room DARKROOM1 at site Sutter Lakeside Hospital

The specific problem noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection. This problem is identified as Level 1, because it identifies a failure to meet a significant MQSA requirement.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed

Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

In addition, your response should address the Level 2 findings that were listed on the inspection report provided to you at the close of the inspection. These Level 2 findings are:

- Level 2: 1 of 6 random reports reviewed did not contain an assessment category for site Sutter Lakeside Hospital
- Level 2: The radiologic technologist did not meet the continuing education requirement of having completed a min. of 15 CEUs in mammography in a 36 month period: [REDACTED] (10.5 CEU's in 36 months)

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).\*

Please submit your response to:

Russell A. Campbell, Compliance Officer  
San Francisco District  
U.S. Food and Drug Administration  
1431 Harbor Bay Parkway  
Alameda, CA 94502

*\*This note is not applicable for letters which also address patient notification*

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Russell A. Campbell at 510-337-6861.

Sincerely yours,

  
Dennis K. Linsley  
District Director